CERo Therapeutics, Inc. is a new cellular immunotherapy company.
Cero Therapeutics has raised $8.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in April 2025.
Cero Therapeutics's investors include HSG, ARCH Venture Partners, Lyell Immunopharma, Altitude Life Science Ventures.
Cero Therapeutics is headquartered in South San Francisco, United States.
CERo Therapeutics, Inc. is a new cellular immunotherapy company.
Cero Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cero Therapeutics — Funding & Investors." VCBacked, April 22, 2025, https://www.vcbacked.co/company/cero-therapeutics. Accessed July 19, 2026.
VCBacked. (2025). Cero Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/cero-therapeutics
{{cite web |title=Cero Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/cero-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated